Afficher la notice abrégée

dc.contributor.editorBurri, Christian
dc.date.accessioned2021-05-01T15:16:04Z
dc.date.available2021-05-01T15:16:04Z
dc.date.issued2020
dc.identifierONIX_20210501_9783039289639_370
dc.identifier.urihttps://directory.doabooks.org/handle/20.500.12854/68624
dc.description.abstractAs it is a goal to eliminate human African trypanosomiasis (HAT; sleeping sickness) as a public health problem by 2020 and interrupt transmission by 2030, this is a good moment to reflect on what we have achieved, what we want to achieve, and what could get in our way. HAT has a reputation for spectacular reappearances, and the latest peak of 40,000 reported and over 300,000 estimated cases only dates back to 1998. Efforts of the WHO and partners as well as the development of simpler and much better-tolerated treatments, improved diagnostics, and vector control tools made it possible to reduce this number by 95%. Case identification and confirmation remain complex and require specific skills, treatment remains error-prone and reports on long-term survivors have emerged, and the relevance of the animal reservoir for T. b. gambiense HAT needs clarification. In addition, to win the “end game” against this massively stigmatized disease, the human factor will play a key role. This Special Issue addresses many of the burning topics about disease elimination in its 12 research and 7 review articles and one case study. The papers critically reflect the approaches used, investigate the mentioned challenges, and propose novel approaches and interventions from various points of view.
dc.languageEnglish
dc.subject.classificationthema EDItEUR::M Medicine and Nursingen_US
dc.subject.classificationthema EDItEUR::M Medicine and Nursing::MB Medicine: general issues::MBN Public health and preventive medicine::MBNS Epidemiology and Medical statisticsen_US
dc.subject.other(+)-spectaline
dc.subject.otheriso-6-spectaline
dc.subject.otherTrypanosoma brucei rhodesiense
dc.subject.otherautophagy
dc.subject.otherapoptosis
dc.subject.othercross-talk
dc.subject.othertrypanosomosis
dc.subject.otheriron
dc.subject.othertransferrin
dc.subject.othertransferrin receptor
dc.subject.othernutritional immunity
dc.subject.otherflagellar pocket
dc.subject.otherHuman African Trypanosomiasis (HAT)
dc.subject.othermydriasis
dc.subject.otherneurological signs
dc.subject.othereradication
dc.subject.otherre-emergence
dc.subject.otherhuman African trypanosomiasis
dc.subject.othertreatment
dc.subject.othermelarsoprol
dc.subject.otheradverse event
dc.subject.otherencephalopathy
dc.subject.otherhuman leukocyte antigen
dc.subject.otherassociation study
dc.subject.otherdisease elimination
dc.subject.otherdisease eradication
dc.subject.otherfrontline workers
dc.subject.otherDR Congo
dc.subject.othermobile screening
dc.subject.otherqualitative methods
dc.subject.othersequelae
dc.subject.otherserology
dc.subject.otheroligosymptomatic HAT
dc.subject.otherproduct development partnerships
dc.subject.otherresearch and development
dc.subject.othermedical innovation
dc.subject.otherdonor policy
dc.subject.otherAfrican trypanosomiasis
dc.subject.othersleeping sickness
dc.subject.othertrypanosoma brucei
dc.subject.otherdrugs
dc.subject.otherdrug resistance
dc.subject.otherhistory
dc.subject.otherhuman Africa trypanosomiasis
dc.subject.otherfexinidazole
dc.subject.otherhome-based treatment
dc.subject.otherpatient-centred care
dc.subject.otherUganda
dc.subject.otherelimination
dc.subject.otherT. b. gambiense
dc.subject.otherg-HAT
dc.subject.otherT. b. rhodesiense
dc.subject.otherr-HAT
dc.subject.otherneglected tropical diseases
dc.subject.otherTrypanosoma brucei
dc.subject.otherdrug discovery
dc.subject.otherhigh-throughput screening
dc.subject.otherblood–brain barrier
dc.subject.otherbrain permeability
dc.subject.otherpharmacology
dc.subject.otherphenotypic drug screening
dc.subject.otherHaemoparasites
dc.subject.otheranimal reservoirs
dc.subject.otherTrypanosoma growth inhibitors
dc.subject.otherchemotherapy
dc.subject.otherpafuramidine
dc.subject.otheracoziborole
dc.subject.otherAfrican sleeping sickness
dc.subject.otherdevelopment of treatment
dc.subject.othersuramin
dc.subject.othermedical history
dc.subject.otherpolitical history
dc.subject.otherclinical research
dc.subject.otherhealth system strengthening
dc.subject.otherSouth Sudan
dc.subject.otherdiagnosis
dc.subject.othersymptoms
dc.subject.othertreatment-seeking
dc.subject.othercase detection
dc.subject.otherembodiment
dc.subject.otherexpertise
dc.subject.otherserendipity
dc.subject.otherCATT positive serological suspects
dc.subject.otheractive follow-up strategy
dc.subject.othern/a
dc.titleHuman African Trypanosomiasis (Sleeping Sickness)
dc.title.alternativeThe Road to Elimination Revisited—Achievements and Remaining Challenges
dc.typebook
oapen.identifier.doi10.3390/books978-3-03928-964-6
oapen.relation.isPublishedBy46cabcaa-dd94-4bfe-87b4-55023c1b36d0
oapen.relation.isbn9783039289639
oapen.relation.isbn9783039289646
oapen.pages280
oapen.place.publicationBasel, Switzerland


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée

https://creativecommons.org/licenses/by/4.0/
Excepté là où spécifié autrement, la license de ce document est décrite en tant que https://creativecommons.org/licenses/by/4.0/